JD‐02, a novel Hsp90 inhibitor, induces ROS/SRC axis‐dependent cytoprotective autophagy in colorectal cancer cells
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23706 ↗At a glance
Journal article in Molecular Carcinogenesis, 2024. Written by Ni Lan and 7 co-authors. Institution: Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital, The Secon…. Major MEDLINE topics: Autophagy, Colorectal Neoplasms, HSP90 Heat-Shock Proteins, Reactive Oxygen Species. Cited 5 times so far (Crossref); 44 references. Funded by: Science and Technology Foundation of Shenzhen, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (original language)
Heat shock protein 90 (Hsp90) is a tumor marker that accelerates cancer growth by disrupting protein homeostasis. However, concerns such as low clinical efficacy and drug resistance continue to be obstacles to the successful marketing of Hsp90 inhibitors. The cytoprotective function of autophagy has been identified as one of the mechanisms by which tumor cells gain resistance to chemotherapy. JD‐02 was identified as a new Hsp90 inhibitor that suppressed colorectal cancer (CRC) growth by lowering client protein levels in vivo and in vitro. We found that JD‐02 increased cellular autophagy, which inhibited apoptosis. JD‐02 enhanced cytoprotective autophagy and regulated apoptotic suppression by increasing intracellular reactive oxygen species and inhibiting SRC protein levels, as demonstrated by quantitative proteomics, bioinformatic analysis, western blotting, and flow cytometry. This effect was reversed by autophagy inhibition. Therefore, due to the synergistic effects of Hsp90 and autophagy inhibitors in efficiently activating apoptotic pathways, they could potentially serve as promising therapeutic options for CRC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Guangdong Provincial Clinical Research Center for Geriatrics, Shenzhen Clinical Research Center for Geriatrics, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen, China.
- Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, China.
- Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
- College of Pharmacy, Jinan University, Guangzhou, China.
ORCID profiles: Kaisheng Liu
Funding
- Science and Technology Foundation of Shenzhen
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- Youth Program of National Natural Science Foundation of China
Cite
APA
Lan, N., Su, Y., Zeng, Q., Zhou, P., Hu, Y., Zhang, Z., Wang, Y., & Liu, K. (2024). JD‐02, a novel Hsp90 inhibitor, induces ROS/SRC axis‐dependent cytoprotective autophagy in colorectal cancer cells. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23706
Vancouver
Lan N, Su Y, Zeng Q, Zhou P, Hu Y, Zhang Z, et al. JD‐02, a novel Hsp90 inhibitor, induces ROS/SRC axis‐dependent cytoprotective autophagy in colorectal cancer cells. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23706
BibTeX
@article{Lan2024,
author = {Lan, Ni and Su, Yuan and Zeng, Qiongzhen and Zhou, Pengjun and Hu, Yuze and Zhang, Zhuo and Wang, Yifei and Liu, Kaisheng},
title = {JD‐02, a novel Hsp90 inhibitor, induces ROS/SRC axis‐dependent cytoprotective autophagy in colorectal cancer cells},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23706}
}
EUVIMED